Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexion's Pipeline Rebuild Plan Targets Wilson's Liver Drug, More M&A Likely

Executive Summary

Swedish target's sole product WTX101 is in Phase III trials for treating Wilson Disease. Alexion says expect more deals. 

You may also be interested in...



Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune

Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Topics

Related Companies

UsernamePublicRestriction

Register

SC122879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel